Dose-dependent Kinetics of Thiamin in Healthy Volunteers With and Without Functional OCT1 Hepatic Transporters
NCT ID: NCT06122701
Last Updated: 2025-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
36 participants
INTERVENTIONAL
2023-11-03
2025-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Cohort 1) OCT1 wild type genotypes n = 12 Cohort 2) OCT1 deficient genotypes n = 12 Participants will be selected according to their OCT1 genotypes and to achieve best matching according to sex, age, BMI, alcohol consumption, and smoking between Cohort 1 and 2, respectively.
The purpose of this study is:
1. To determine the influence of OCT1 genetic variants on dose-dependent thiamin kinetics after oral administration.
2. To elucidate whether OCT1 genetic variants impact the kinetic properties of orally vs. intravenously administered thiamin.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics of Oral Thiamine
NCT01433952
Pharmacokinetic Effects of Oral DMAA
NCT01765933
Pharmacokinetics of Trans-resveratrol Based Nutritional Supplement and Its Three Metabolites in Human Eyes and Blood
NCT02321176
Reproducibility of Acute Caffeine Effect
NCT06606639
Pharmacokinetic Analysis of Nicotinamide Riboside
NCT02300740
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A single oral dose of thiamin will be administered in four intervention arms (arm 1: 200 mg, arm 2: 50 mg, arm 3: 10 mg, arm 4: 5 mg) as a drinking solution with 240 ml of still water after an overnight fast. These four arms will be put into practice at the same time with each participant completing all four arms in random order with a wash-out period of at least one week between each arm.
After analyzing the four oral arms, we decided to administer a single i.v. dose of 5 mg thiamin in arm 5.
A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. At baseline, 2x 2.7 ml EDTA blood samples will be collected for DNA isolation if the particular volunteer has not had a genotypical validation in another study of our Institute.
The total amount of blood collected for each participant is 456 ml at eight kinetic visits and 10 ml at the Screening.
After intake of the thiamin solution, participants will drink 100 ml of sparkling water every hour to stimulate gastrointestinal peristalsis. After 4 hours the participants will be served a meal low in thiamin content. Urine will be collected during the first 10 hours after thiamin administration. Monitoring of blood pressure and heart rate will take place for the first 4 hours after administration. Volunteers will stay in the Clinical Research Unit of the Institute of Pharmacology for the first 10 hours after administration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OCT1 deficient and wild type genotypes: 200 mg thiamin p.o.
The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between cohort 1 and cohort 2.
Thiamin p.o.
A single oral dose of thiamin will be administered in four intervention arms (arm 1: 200 mg, arm 2: 50 mg, arm 3: 10 mg, arm 4: 5 mg) as a drinking solution with 240 ml of still water after an overnight fast.
A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration.
OCT1 deficient and wild type genotypes: 50 mg thiamin p.o.
The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between cohort 1 and cohort 2.
Thiamin p.o.
A single oral dose of thiamin will be administered in four intervention arms (arm 1: 200 mg, arm 2: 50 mg, arm 3: 10 mg, arm 4: 5 mg) as a drinking solution with 240 ml of still water after an overnight fast.
A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration.
OCT1 deficient and wild type genotypes: 10 mg thiamin p.o.
The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between cohort 1 and cohort 2.
Thiamin p.o.
A single oral dose of thiamin will be administered in four intervention arms (arm 1: 200 mg, arm 2: 50 mg, arm 3: 10 mg, arm 4: 5 mg) as a drinking solution with 240 ml of still water after an overnight fast.
A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration.
OCT1 deficient and wild type genotypes: 5 mg thiamin p.o.
The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between cohort 1 and cohort 2.
Thiamin p.o.
A single oral dose of thiamin will be administered in four intervention arms (arm 1: 200 mg, arm 2: 50 mg, arm 3: 10 mg, arm 4: 5 mg) as a drinking solution with 240 ml of still water after an overnight fast.
A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration.
OCT1 deficient and wild type genotypes: 5 mg thiamin i.v.
The participants are selected to achieve best matching according to sex, age, BMI, alcohol consumption and smoking between cohort 1 and cohort 2.
Thiamin i.v.
A single i.v. dose of thiamin 5 mg with 240 ml of still water after an overnight fast.
A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thiamin p.o.
A single oral dose of thiamin will be administered in four intervention arms (arm 1: 200 mg, arm 2: 50 mg, arm 3: 10 mg, arm 4: 5 mg) as a drinking solution with 240 ml of still water after an overnight fast.
A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration.
Thiamin i.v.
A single i.v. dose of thiamin 5 mg with 240 ml of still water after an overnight fast.
A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. age between 18 and 50 years
3. OCT1 wild type: homozygous for OCT1\*1 OCT "poor transporter": homozygous or heterozygous for OCT1\*3, \*4, \*5, \*6
4. understands the study purpose and design
5. contractually capable and provides signed informed consent form
6. healthy condition or mild and/or well-treated forms of allergies, asthma, hypertension, and orthopedic diseases
7. a maximum of 3 chronically taken drugs not interfering with OCT1 activity
Exclusion Criteria
2. body weight \< 48 kg
3. known pregnancy or lactation period
4. women: positive urine pregnancy test at screening or kinetic visit 1 of each arm
5. men: hemoglobin \< 13 g/dl (8,07 mmol/l) women: hemoglobin \< 12 g/dl (7,45 mmol/l)
6. elevated liver function tests (1 or more of ALAT, ASAT, yGT, Bilirubin \> 2x ULN)
7. reduced renal function (eGFRMDRD \< 60 ml/min/1,7 m2)
8. QTcF \> 450 ms in screening ECG
9. psychiatric disease requiring recent or actual treatment
10. drug dependency at the time of visit
11. use of recreational drugs more than twice a week
12. any known hypersensitivity or allergic reactions to thiamin
13. history of severe hypersensitivity reactions and/or anaphylaxis
14. clinically proven vitamin B1 deficiency
15. individuals taking regular vitamin B1 or multi-vitamin supplements who are not willing to comply with a 48-hour washout of these supplements before each kinetic visit
16. individuals who have taken vitamin B supplements or multi-vitamins in the past 2 days before kinetic visit 1 of each arm
17. poor venous conditions that make it impossible to place a peripheral venous catheter and regularly draw blood through it
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medicine Greifswald
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stefan Engeli, MD
Prof. Dr. med Stefan Engeli
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stefan Engeli
Role: PRINCIPAL_INVESTIGATOR
Universitätsmedizin Greifswald, Institut für Pharmakologie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medicine Greifswald, Institute of Pharmacology
Greifswald, Mecklenburg-Vorpommern, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IPHA-2023-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.